Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. (DCPH): 12 pipeline candidates · ~9 mo cash runway · 16 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.3 months
D/E 0.33 · 6% dilution
Lead: Approved
12 candidates
N/A
N/A
A transparent, data-derived signal for Deciphera Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$91.2M
Quarterly Burn
$54.6M
Runway
9.3 mo
Revenue
$45.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| combined oral contraceptive | Phase 1 |
| dcc-2812 | Phase 1 |
| dcc-3009 | Phase 1/Phase 2 |
| dcc-3084 | Phase 1/Phase 2 |
| dcc-3116 | Phase 1/Phase 2 |
| inlexisertib | Phase 1/Phase 2 |
| qinlock | Approved |
| romvimza | Approved |
| rosuvastatin | Phase 1 |
| sapablursen | Phase 3 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Deciphera Pharmaceuticals, Inc.'s pipeline?
Deciphera Pharmaceuticals, Inc. (DCPH) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Deciphera Pharmaceuticals, Inc.'s lead drug candidate?
Deciphera Pharmaceuticals, Inc.'s most advanced tracked candidate is combined oral contraceptive (Phase 1) for Healthy Participants.
What is Deciphera Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Deciphera Pharmaceuticals, Inc. has approximately 9.3 months of cash runway.
Who is the CEO of Deciphera Pharmaceuticals, Inc.?
Massachusetts April is the chief executive officer of Deciphera Pharmaceuticals, Inc. (DCPH).
Get the full picture on Deciphera Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.